TY - JOUR
T1 - Mitochondrial DNA and TLR9 drive muscle inflammation upon Opa1 deficiency
AU - Rodríguez-Nuevo, Aida
AU - Díaz-Ramos, Angels
AU - Noguera, Eduar D.
AU - Díaz-Sáez, Francisco
AU - Duran, Xavier
AU - Muñoz, Juan Pablo
AU - Romero, Montserrat
AU - Plana, Natàlia
AU - Sebastián, Davi D.
AU - Tezze, Caterina
AU - Romanello, Vanina
AU - Ribas, Francesc
AU - Seco, Jordi
AU - Planet, Evarist
AU - Doctrow, Susan R.
AU - González, Javier
AU - Borràs, Miquel
AU - Liesa, Marc
AU - Palacín, Manuel
AU - Vendrell, Joan
AU - Villarroya, Francesc
AU - Sandri, Marco
AU - Shirihai, Orian
AU - Zorzano, Antonio
N1 - Publisher Copyright:
© 2018 The Authors
PY - 2018/5/15
Y1 - 2018/5/15
N2 - Opa1 participates in inner mitochondrial membrane fusion and cristae morphogenesis. Here, we show that muscle-specific Opa1 ablation causes reduced muscle fiber size, dysfunctional mitochondria, enhanced Fgf21, and muscle inflammation characterized by NF-κB activation, and enhanced expression of pro-inflammatory genes. Chronic sodium salicylate treatment ameliorated muscle alterations and reduced the muscle expression of Fgf21. Muscle inflammation was an early event during the progression of the disease and occurred before macrophage infiltration, indicating that it is a primary response to Opa1 deficiency. Moreover, Opa1 repression in muscle cells also resulted in NF-κB activation and inflammation in the absence of necrosis and/or apoptosis, thereby revealing that the activation is a cell-autonomous process and independent of cell death. The effects of Opa1 deficiency on the expression NF-κB target genes and inflammation were absent upon mitochondrial DNA depletion. Under Opa1 deficiency, blockage or repression of TLR9 prevented NF-κB activation and inflammation. Taken together, our results reveal that Opa1 deficiency in muscle causes initial mitochondrial alterations that lead to TLR9 activation, and inflammation, which contributes to enhanced Fgf21 expression and to growth impairment.
AB - Opa1 participates in inner mitochondrial membrane fusion and cristae morphogenesis. Here, we show that muscle-specific Opa1 ablation causes reduced muscle fiber size, dysfunctional mitochondria, enhanced Fgf21, and muscle inflammation characterized by NF-κB activation, and enhanced expression of pro-inflammatory genes. Chronic sodium salicylate treatment ameliorated muscle alterations and reduced the muscle expression of Fgf21. Muscle inflammation was an early event during the progression of the disease and occurred before macrophage infiltration, indicating that it is a primary response to Opa1 deficiency. Moreover, Opa1 repression in muscle cells also resulted in NF-κB activation and inflammation in the absence of necrosis and/or apoptosis, thereby revealing that the activation is a cell-autonomous process and independent of cell death. The effects of Opa1 deficiency on the expression NF-κB target genes and inflammation were absent upon mitochondrial DNA depletion. Under Opa1 deficiency, blockage or repression of TLR9 prevented NF-κB activation and inflammation. Taken together, our results reveal that Opa1 deficiency in muscle causes initial mitochondrial alterations that lead to TLR9 activation, and inflammation, which contributes to enhanced Fgf21 expression and to growth impairment.
KW - endosome
KW - mitochondrial dynamics
KW - muscle disease
KW - systemic inflammation
UR - http://www.scopus.com/inward/record.url?scp=85044960269&partnerID=8YFLogxK
U2 - 10.15252/embj.201796553
DO - 10.15252/embj.201796553
M3 - Article
AN - SCOPUS:85044960269
SN - 0261-4189
VL - 37
JO - EMBO Journal
JF - EMBO Journal
IS - 10
M1 - e96553
ER -